Methods and compositions for reducing
The present invention relates to methods and compositions for reducing the risk and severity of C. difficile infection. It is based, at least in part, on the discovery that a restricted fraction of the gut microbiota, including the bacterium Clostridium scindens , contributes substantially to resistance against C. difficile infection. Without being bound by any particular theory, it is believed that this is achieved through the biosynthesis of secondary bile acids.
1. A method for reducing the risk of Clostridium difficile infection or reducing the severity of Clostridium difficile infection in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a composition, which comprises at least one isolated bacteria or spores thereof, which is selected from Clostridiales VE202-05, Clostridiales VE202-26, or both.
2. The method of claim 1 , wherein the composition further comprises one or more additional isolated bacteria or spores thereof, which is selected from Clostridium scindens, Clostridium hiranonis, Clostridium hylemonae, Clostridium perfringens, Clostridium sordelli, Proteocatella sphenisci , Lachnospiraceae 5_1_57FAA, Barnesiella intestihominis, Blautia hansenii, Pseudoflavonifractor capillosus , or combinations thereof.
3. The method of claim 1 , wherein one or more of the isolated bacteria or spores thereof of the composition are capable of engrafting in the gastrointestinal tract of the subject.
4. The method of claim 1 , wherein administering the composition increases the amount of a secondary bile acid in the gastrointestinal tract of the subject.
5. The method of claim 1 , further comprising administering to the subject an antibiotic, an immunotherapeutic agent, an herbal remedy, a probiotic, or combinations thereof.
6. The method of claim 5 , wherein the antibiotic comprises a vancomycin, a metronidazole, a fidaxomicin, or combinations thereof.
7. The method of claim 5 , wherein the antibiotic is not selected from the group consisting of a β-lactam antibiotic, a clindamycin, a cephalosporin, a quinolone antibiotic, a levofloxacin, a fluoroquinolone, a macrolide antibiotic, a trimethoprim, a sulfonamide antibiotic, and combinations thereof.
8. The method of claim 1 , wherein the subject is receiving an antibiotic therapy.
9. The method of claim 2 , wherein the additional isolated bacteria or spores thereof is Clostridium scindens.
10. The method of claim 2 , wherein the additional isolated bacteria or spores thereof is Pseudoflavonifractor capillosus.
11. The method of claim 1 , wherein the composition is administered to the subject via oral or rectal administration.
12. The method of claim 1 , wherein one or more of the isolated bacteria or spores thereof of the composition are lyophilized.
13. The method of claim 1 , wherein the subject has previously suffered a Clostridium difficile infection.
14. A method for reducing the risk of developing Clostridium difficile -associated disease or treating a Clostridium difficile -associated disease in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a composition, which comprises at least one isolated bacteria or spores thereof, which is selected from Clostridiales VE202-05, Clostridiales VE202-26, or both.
15. The method of claim 14 , wherein the composition further comprises one or more additional isolated bacteria or spores thereof, which is selected from Clostridium scindens, Clostridium hiranonis, Clostridium hylemonae, Clostridium perfringens, Clostridium sordelli, Proteocatella sphenisci , Lachnospiraceae 5_1_57FAA, Barnesiella intestihominis, Blautia hansenii, Pseudoflavonifractor capillosus , or combinations thereof.
16. The method of claim 14 , wherein the Clostridium difficile -associated disease comprises a Clostridium difficile colitis, a pseudomembranous colitis, or both.